Company
Subiaco, WA
Every investor coverage indicates participated in a round Identifai Genetics Limited raised.
The transaction that ended Identifai Genetics Limited's run as a startup, per published coverage. It closes the funding history too, where it is the ladder's last rung.
| Bought by | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| - | IPO | 9 Oct 2026 | ~$38.4m | Business News Australia, Mirage News, Dealroom |
Companies Identifai Genetics Limited acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Sebastian Andre | Company Secretary | Dealroom |
| Eyal Miller | CEO | Business News Australia, Mirage News |
Stories naming Identifai Genetics Limited. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Identifai Genetics has joined the ASX after raising about US$6.47 million in its IPO, with proceeds going toward its non-invasive prenatal screening platform Windrose; Aesir Corporate managed the offer.